Clinical Trial

Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department

Name: Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department — clinical trial record (NCT07246187)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CH2O

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.

Trial Details

NCT Number	NCT07246187
Lead Sponsor	Mercy Bon Secours Saint Vincent Medical Center
Conditions	Cannabinoid Hyperemesis Syndrome
Enrollment	114 participants
Start Date	2025-11-06
Primary Completion	2026-10-31 (estimated)
Study Completion	2026-11 (estimated)
Updated on ClinicalTrials.gov	2025-11-24